Back to first-pass browser

First-pass extracted concept

anti-CD19-CD28ζ CAR with CD8α hinge

Candidate: toolkit itemType: multi component switch1 source documents4 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

anti-CD19 CAR T construct, anti-CD19-CD28ζ CAR, CD19 CAR

Extracted Explainers

What the tool is doing

This engineered CAR receptor redirects peripheral blood αβ T cells to recognize CD19-expressing cells and mediate antigen-specific effector responses in vitro. The construct uses a CD8α hinge, CD28 transmembrane/co-stimulatory region, and CD3ζ signaling domain.

Source 1DOIPubMed

Resources required

The abstract supports requirements for peripheral blood αβ T cells, CD3/CD28 bead prestimulation, lentiviral transduction, and ex vivo expansion in serum-free media. Functional testing used CD19+ NALM6 target cells and a flow-cytometry-based killing assay.

Source 1DOIPubMed

What problem it solves

The construct is presented as a way to generate anti-CD19 CAR T cells for adoptive immunotherapy against diseases driven by CD19+ B-lineage cells.

Source 1DOIPubMed

What it does not solve

The provided evidence does not show in vivo efficacy, clinical safety, or performance beyond the reported in vitro workflow and assays.

Source 1DOIPubMed

Alternatives

The source does not explicitly compare this construct against another CAR architecture within the abstract.

Source 1DOIPubMed

Evidence Snippets

CAR construct containing hinge domain from CD8α, transmembrane and co-stimulatory domain from CD28 along with signaling domain from CD3ζ and driven by human UBC promoter.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1construct designsupports2025Source 1DOIPubMed

The anti-CD19 CAR construct used a CD8α hinge, CD28 transmembrane and co-stimulatory domains, CD3ζ signaling domain, and a human UBC promoter.

Claim 2engineering approachsupports2025Source 1DOIPubMed

The paper reports a safer approach for engineering peripheral blood αβ T cells with an anti-CD19-CD28ζ CAR using self-inactivating lentiviral vectors.

Claim 3expansion and viabilitysupports2025Source 1DOIPubMed

The anti-CD19 CAR T cells expanded in serum-free media with high viability by day 12.

Claim 4functional activitysupports2025Source 1DOIPubMed

The anti-CD19 CAR T cells showed antigen-specific in vitro activity against CD19-expressing NALM6 cells, including target lysis, IFNγ production, and CD107α degranulation.